Abstract Background Vitiligo is the most common pigmentary disorder and is considered a chronic, cumulative, multifactorial disease. The crucial role of cytotoxic CD8+ T lymphocytes and the IFNγ/CXCL10 axis has been demonstrated in its pathogenesis. Objective To evaluate the clinical profile and immuno-inflammatory markers in patients with vitiligo in a reference medical center. Methods Cross-sectional study in which all patients with vitiligo seen at the medical center the from 2019 to 2022 were evaluated, to outline the clinical profile. Moreover, cardiovascular risk biomarkers (neutrophil/lymphocyte ratio and C-reactive protein levels) were measured, as well as cytokines and chemokines (TNFα, IFNγ, IL10, IL15 and CXCL10) in the serum of a subgroup of 30 patients. Results There was a predominance of females, with a mean age of 43 years. Most were phototypes IV or V (71.3%), without comorbidities (77.55%), and without a family history of vitiligo (70.41%). Higher levels of neutrophil/lymphocyte ratio, C-reactive protein, and inflammatory cytokines/chemokines were documented in vitiligo patients when compared to the control group (non-significant). As relevant data, the highest values of CXCL10 were detected in patients with vitiligo versus controls, as well as in patients with disease of shorter duration (p < 0.05). Study limitations The number of assessed patients was small due to recruitment difficulties caused by the COVID-19 pandemic. Conclusion The present data contribute to confirming the relevant role of the IFNγ/CXCL10 axis in the pathogenesis of vitiligo, highlighting CXCL10 as a possible activity marker. chronic cumulative CD8 CD IFNγCXCL10 IFNγCXCL IFNγ CXCL IFNγ/CXCL1 immunoinflammatory immuno Crosssectional Cross sectional 201 202 evaluated Moreover neutrophillymphocyte neutrophil lymphocyte Creactive C reactive measured TNFα, TNFα (TNFα IL10 IL IL1 3 females 4 years 71.3%, 713 71.3% , 71 (71.3%) 77.55%, 7755 77.55% 77 55 (77.55%) 70.41%. 7041 70.41% . 70 41 (70.41%) cytokineschemokines nonsignificant. nonsignificant non significant (non-significant) CXCL1 controls p 0.05. 005 0.05 0 05 0.05) COVID19 COVID 19 COVID-1 pandemic marker IFNγCXCL1 IFNγ/CXCL 20 71.3 7 (71.3% 775 77.55 5 (77.55% 704 70.41 (70.41% (non-significant 00 0.0 COVID1 1 COVID- 2 71. (71.3 77.5 (77.55 70.4 (70.41 0. (71. 77. (77.5 70. (70.4 (71 (77. (70. (7 (77 (70 (

OBJETIVO: A terapia analgésica eficaz no pós-operatório de artroplastia total do joelho é imprescindível para bons resultados cirúrgicos. A tendência atual é a de se utilizar o tratamento multimodal, no qual a utilização de emplastros com lidocaína como terapia adjuvante tem papel crescente e relevante. Investigar os potenciais benefícios da associação do emplastro com lidocaína ao esquema terapêutico básico de analgesia para o alívio da dor durante o período pós-operatório de artroplastia total de joelho. MÉTODO: Foi realizado um estudo de coorte retrospectivo cuja população foi a de pacientes submetidos a artroplastia total do joelho, divididos em dois grupos com 24 integrantes em cada, acompanhados por um período de 28 dias. RESULTADOS: Durante o pós-operatório analisado a dor foi menos intensa nos pacientes que utilizaram os emplastros com lidocaína. Nesses mesmos pacientes, as doses de opióides necessárias para controlar a dor foram menores em 15 dos 28 dias analisados. A frequência relativa de náuseas foi maior no grupo que não utilizou a terapia adjuvante. Predominaram os pacientes com mais de 70 anos e o gênero feminino. CONCLUSÃO: O tratamento adjuvante após a artroplastia total do joelho utilizando emplastros com lidocaína mostrou ser eficaz na redução da dor e diminuição do uso de opióides no período analisado, constituindo um bom incremento para a terapia analgésica multimodal.

BACKGROUND: Effective analgesic therapy in the postoperative period of total knee arthroplasty is essential for good surgical outcomes. The current trend is to use multimodal treatment, in which the use of patches with lidocaine as adjuvant therapy has an increasingly relevant role. OBJECTIVE: To investigate the potential benefits of lidocaine patch association with the basic analgesia regimen for pain relief during the postoperative period of total knee arthroplasty. METHOD: A retrospective cohort study was performed , with a total of 24 patients in each group, who underwent total knee arthroplasty. Pain levels using a visual analogue scale and opioid intake were controlled from the immediate postoperative to the end of a 28-day interval. RESULTS: During the postoperative period, pain was less intense in patients who used lidocaine patches. In these same patients, the doses of opioids needed to control pain were lower in 15 of the 28 days analyzed. The relative frequency of nausea was higher in the group that did not use adjuvant therapy. Patients older than 70 years and females predominated. CONCLUSION: Adjuvant treatment after total knee arthroplasty using lidocaine patches was effective in reducing pain and decreasing the use of opioids in the period analyzed, and represents a good addition to multimodal analgesic therapy.